摘要
[目的]对行初次全膝关节表面置换术患者的个性化围术期血液管理方案进行临床疗效评价。[方法]对2011年12月~2016年12月在本院关节外科进行初次单侧全膝关节表面置换术的478例病例进行回顾性分析。实施围术期血液管理方案的患者共263例为试验组;未施行围术期血液管理方案的患者共215例为对照组。分别记录两组的术前及术后血红蛋白含量(术后第3 d),术中出血量,术后引流量,血制品输注量及住院时间。[结果]试验组患者术中出血量、术后引流量、输血量和输血率、术后血红蛋白下降量均少于对照组,差异均有统计学意义(P<0.05)。另外,试验组患者的平均住院日稍高于对照组,但差异无统计学意义(P>0.05)。[结论]依据患者实际情况,制定和应用个性化全膝关节置换术围术期血液管理方案十分必要,可以减少围手术期失血,促进患者早期恢复。
[Objective] To evaluate the clinical efficacy of perioperative personalized blood management in total knee arthroplasty. [Methods] A retrospective analysis was done on 478 patients who underwent primary unilateral total knee arthroplasty in our department from December 2011 to December 2016. Of them, 263 patients who received perioperative personalized blood management were described as the trial group, while the other 215 patients without perioperative blood management were enrolled into the control group. The intraoperative bleeding, postoperative drainage, blood transfusion, hospital stay as well as hemoglobin decline（the difference between that preoperatively and 3 days after operation） were compared between the two groups. [Results] The intraoperative bleeding, drainage, volume and rate of blood transfusion as well as hemoglobin decline in the trial group were significantly less than those in the control group with statistical differences between the two groups（P〈0.05）. However, the average hospital days in the trail group slightly higher than the control group although there was not a statistical difference between them（P〉0.05）. [Conclusion] It is necessary to formulate and practice a perioperative personalized blood management for the total knee arthroplasty based on the actual situation of each patient to reduce perioperative blood loss and facilitate early recovery.
作者
丁星
赵畅
蔡道章
DING Xing;ZHAO Chang;CAI Dao-zhang(The Third Affiliated Hospital of Southern Medical University,Guangzhou 510630,China)
出处
《中国矫形外科杂志》
CAS
CSCD
北大核心
2018年第15期1350-1355,共6页
Orthopedic Journal of China
关键词
全膝关节表面置换术
血液管理方案
异体输血
total knee arthroplasty
perioperative blood management
allogenetic transfusion
